Adult anaplastic ependymoma
diseaseOn this page
Also known as adult malignant ependymomaanaplastic ependymomaanaplastic ependymoma of adultsmalignant adult ependymoma
Summary
Adult anaplastic ependymoma (MONDO:0003690) is a disease and 30 clinical trials. Molecularly, KANK1::NTRK2 Fusion confers sensitivity to Larotrectinib in Anaplastic Ependymoma (CIViC Level C). Top therapeutic interventions include 2-mercaptoethanesulfonic acid, edotreotide gallium ga-68, and fluorodopa f 18. A subtype of anaplastic ependymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 30
- Precision-medicine evidence (CIViC): 1 subtype–drug association
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult anaplastic ependymoma |
| Mondo ID | MONDO:0003690 |
| DOID | DOID:5890 |
| NCIT | C8269 |
| UMLS | C0280787 |
| MedGen | 83709 |
| GARD | 0023619 |
| Is cancer (heuristic) | no |
Also known as: adult anaplastic ependymoma · adult malignant ependymoma · anaplastic ependymoma · anaplastic ependymoma of adults · malignant adult ependymoma
Disease family
This is a subtype of anaplastic ependymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › ependymal tumor › anaplastic ependymoma › adult anaplastic ependymoma
Related subtypes (2): posterior fossa ependymoma, supratentorial ependymoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 30.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 13 |
| PHASE2 | 7 |
| Not specified | 5 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01096368 | PHASE3 | COMPLETED | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma |
| NCT05278208 | PHASE1/PHASE2 | RECRUITING | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors |
| NCT00243490 | PHASE2 | WITHDRAWN | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors |
| NCT00492089 | PHASE2 | COMPLETED | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
| NCT01095094 | PHASE2 | TERMINATED | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma |
| NCT01295944 | PHASE2 | COMPLETED | Carboplatin and Bevacizumab for Recurrent Ependymoma |
| NCT01478321 | PHASE2 | TERMINATED | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas |
| NCT01721577 | PHASE1/PHASE2 | TERMINATED | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas |
| NCT01836549 | PHASE2 | TERMINATED | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors |
| NCT03727841 | PHASE2 | TERMINATED | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma |
| NCT03750513 | PHASE1 | RECRUITING | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma |
| NCT04978727 | PHASE1 | ACTIVE_NOT_RECRUITING | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma |
| NCT00030498 | PHASE1 | COMPLETED | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
| NCT00110032 | PHASE1 | TERMINATED | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors |
| NCT01082926 | PHASE1 | COMPLETED | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 |
| NCT01119599 | PHASE1 | COMPLETED | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
| NCT01131234 | PHASE1 | COMPLETED | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors |
| NCT01234740 | PHASE1 | COMPLETED | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases |
| NCT02101905 | PHASE1 | COMPLETED | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma |
| NCT02186509 | PHASE1 | COMPLETED | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas |
| NCT02722512 | PHASE1 | TERMINATED | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine |
| NCT03434262 | PHASE1 | COMPLETED | SJDAWN: St. Jude Children’s Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
| NCT04521946 | PHASE1 | WITHDRAWN | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer |
| NCT01165632 | EARLY_PHASE1 | COMPLETED | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma |
| NCT01996527 | EARLY_PHASE1 | TERMINATED | 3T MRI Biomarkers of Glioma Treatment Response |
| NCT00430079 | Not specified | TERMINATED | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma |
| NCT01234805 | Not specified | TERMINATED | Yoga Therapy in Treating Patients With Malignant Brain Tumors |
| NCT02175745 | Not specified | TERMINATED | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas |
| NCT02194452 | Not specified | WITHDRAWN | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
| NCT02967380 | Not specified | TERMINATED | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| 2-MERCAPTOETHANESULFONIC ACID | 4 | 2 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| FLUORODOPA F 18 | 4 | 1 |
| GADOBENATE DIMEGLUMINE | 4 | 1 |
| GADOBUTROL | 4 | 1 |
| GADOPENTETATE DIMEGLUMINE | 4 | 1 |
| IMETELSTAT SODIUM | 4 | 1 |
| SONIDEGIB | 4 | 1 |
| VINCRISTINE | 4 | 1 |
| ALISERTIB | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| MARIZOMIB | 3 | 1 |
| AXL-1717 | 2 | 1 |
| BAFETINIB | 2 | 1 |
| ETANIDAZOLE | 2 | 1 |
Precision-medicine subtype map (CIViC)
Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.
| Molecular subtype | Therapy | Effect | Level | CIViC |
|---|---|---|---|---|
| KANK1::NTRK2 Fusion | Larotrectinib | Sensitivity/Response | CIViC C | EID10360 |